Amneal (AMRX) Co-CEO Chintu Patel Receives 6.38M Shares

What Happened Chintu Patel, Co-CEO and director of Amneal Pharmaceuticals (AMRX), received 6,381,734 shares of Amneal Class A common stock on August 10, 2026. The shares were issued as consideration in Amneal’s acquisition of Kashiv BioSciences; no per-share cash price was reported on the Form 4.

Key Details

• Transaction date: August 10, 2026 (reported on Form 4 filed August 12, 2026).
• Transaction type: Award/Acquisition (code A). Shares received: 6,381,734 Class A common shares. Price per share: N/A (shares issued as deal consideration).
• Footnote: The issuance arose from a Membership Interest Purchase Agreement where Amneal acquired 100% of Kashiv for $375 million in cash (subject to adjustments) and issuance of 28,942,098 Amneal Class A shares; Patel-managed LLCs received 6,381,734 of those shares.
• Shares owned after transaction: Not specified in the supplied summary.
• Filing timeliness: Form 4 was filed two days after the transaction date; the filing as provided does not flag a late filing.

Context These shares were issued as part of an M&A consideration package (not an open-market purchase or a sale). Such transfers reflect deal consideration paid to sellers/affiliates rather than a direct cash investment by the insider; they should be viewed as transaction-related equity issuance rather than a straightforward insider "buy" signal.